Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04114903
Other study ID # 1R01DA050515
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 8, 2019
Est. completion date May 31, 2024

Study information

Verified date May 2023
Source University of Colorado, Boulder
Contact Gregory Giordano, MS
Phone 303-492-9549
Email sonic.custudy@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study tests the effects of cannabinoid levels in blood on inflammation and insulin sensitivity both acutely and chronically in individuals across the weight spectrum. To that end, the study employs two observational designs: 1) A study of acute effects with intermittent cannabis users and 2) A study in which current cannabis users will select one of three cannabis strains for four weeks and are compared to a matched control group who do not use cannabis to study chronic effects. Blood levels of THC and CBD, inflammatory biomarkers, and insulin resistance will be measured in both studies.


Description:

According to the National Institute of Diabetes and Digestive and Kidney Diseases, over 30 million people in the US have diabetes, and just over 84 million people have pre-diabetes. Concurrently, 30 states and the District of Columbia have legalized cannabis for medical and/or recreational use and over the past decade, cannabis use among adults has more than doubled. Public perception and some scientific data suggest that cannabis causes acute over-eating, creating concern that public and legal acceptance of cannabis use will worsen the obesity epidemic in the United States, where more than two-thirds of US adults (68.8%) are currently overweight or obese. Paradoxically, cross sectional data demonstrate associations between chronic cannabis use and lower body mass index (BMI), prevalence of obesity, insulin resistance, waist circumference, and actual rates of type 2 diabetes despite data supporting higher caloric intake acutely. This study examines the effects of cannabinoid levels in blood on inflammation and insulin sensitivity both acutely and chronically in individuals across the weight spectrum. To that end, the study employs two observational designs: 1) A study of acute effects with intermittent cannabis users and 2) A study in which current cannabis users will select one of three cannabis strains for four weeks and are compared to a matched control group who do not use cannabis to study chronic effects.


Recruitment information / eligibility

Status Recruiting
Enrollment 214
Est. completion date May 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers
Gender All
Age group 21 Years to 40 Years
Eligibility Inclusion Criteria: - Able to provide informed consent - Cannabis users in Study A must have smoked or vaped cannabis at least once since January 1st 2014 with no negative effects but NOT used in the past three months - Cannabis users in Study B must have been a regular (at least weekly) user for at least a year - Non-users in Study B cannot have used any cannabis in the previous year - Weight stable (<5 pound fluctuation in the past six months) - Planning to remain in the Boulder-Denver area for the next month - Fasting blood glucose greater than or equal to 55 mg/dl and less than or equal to 126 mg/dl - Cannabis users in Study A must endorse knowledge of the procedure(s) for smoking or vaping cannabis Exclusion Criteria: - Known auto-immune disease - Report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs - Daily tobacco (cigarette, E-cigs, smokeless) user, given the impact of tobacco smoking on insulin function - Blood alcohol level greater than 0 at screening - Current use of medications for glucose lowering, immunosuppression, or anti-inflammation - Acute illness - Current use of psychotropic medications - Current diagnosis of diabetes - Heavy drinking as defined by an Alcohol Use Disorders Test (AUDIT) - Females can not be pregnant or trying to become pregnant - Females can not be nursing mothers - Have donated blood in the 8 weeks before the study or intend to donate blood in the 8 weeks after the study.

Study Design


Locations

Country Name City State
United States Center for Innovation and Creativity Boulder Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Boulder University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Daily online survey of cannabis use, alcohol use, exercise and diet Daily surveys sent to Study B participants during the four-week period between study visits querying for cannabis use, alcohol use, minutes of exercise, and consumption of fruits and vegetables Study B only: Daily for four weeks between baseline and second study visit
Primary Markers of Inflammation Change in Circulating Levels of Cytokines (TNF-a, IL-1B, IL-4, IL-6, IL-10, IL-13, MCP-1) Study A: Difference between cytokines at baseline and cytokines one week later after acute use of cannabis product. Study B: Change from baseline to four weeks
Primary Change in Matsuda Index of Insulin Sensitivity Calculation of Insulin Sensitivity using changes in fasting plasma glucose (FPG) and fasting plasma insulin (FPI).
Measurements are collected on venous blood samples at 0, 30, 60, 90, and 120 minutes after ingestion of 75 grams oral glucose during oral glucose tolerance test (OGTT)
Matsuda Index is calculated as follows: 10000/sqrt ((FPG X FPI) X (Mean OGTT glucose concentration X Mean OGTT insulin concentration))
Study A: Baseline versus after acute use one week later of cannabis product. Study B: The two tests will be separated by four weeks
Primary Change in Plasma Glucose Change in glucose over time after ingestion of 75 grams oral glucose measured during during oral glucose tolerance test (OGTT). Measurements are collected on venous blood samples at 0, 30, 60, 90, and 120 minutes. Study A: Baseline versus one week later after acute use of cannabis product. Study B: The two tests will be separated by four weeks
Primary Change in Plasma Insulin Change in insulin over time after ingestion of 75 grams oral glucose measured during OGTT. Measurements are collected on venous blood samples at 0, 30, 60, 90, and 120 minutes. Study A: Baseline versus one week later after acute use of cannabis product. Study B: The two tests will be separated by four weeks
Secondary Stanford Seven-Day Physical Activity Recall (PAR) Interviewer administered assessment of number of minutes of mild, moderate, and vigorous physical activity over the previous seven days. Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
Secondary Sleep Quality Pittsburgh Sleep Quality Index: Measurement of the quality and patterns of sleep from poor to good measuring seven domains (e.g., latency, duration, disturbances) over the last 2 weeks. Study A: Baseline to one week following baseline Study B: Baseline to four weeks following baseline
Secondary Marijuana Consumption Questionnaire Frequency and quantity of cannabis use, age of first use, peer use, perceived risk from cannabis, and perceived availability of cannabis Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
Secondary Marijuana Dependence Scale Based on DSM V criteria that were converted to a self-report to assess dependence and other problems related to the use of cannabis Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
Secondary Marijuana Withdrawal Checklist A 15-item scale used to collect information on withdrawal symptoms participants may be experiencing due to lack of use of marijuana Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
Secondary The Alcohol Use Disorder Identification Test (AUDIT) Standardized assessment of the extent of alcohol use and problems related to alcohol use Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
Secondary Timeline Follow-Back of Substance Use Calendar-based assessment of daily substance use for the 30 days prior to the baseline session only for both studies Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
Secondary SF-12 Health Survey The SF-12 Health Survey is a 12-item questionnaire used to assess general health and well-being and includes domains of physical functioning, role-physical, pain, general health, vitality, social functioning, role-emotional and mental health Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
Secondary Nutrition Data System for Research 24-Hour Dietary Recall Interviewer administered recall measure developed by the University of Minnesota Nutrition Coordinating Center (NCC), that facilitates the standardized collection of 24-hour dietary recall data Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
Secondary Stanford Leisure-Time Activity Categorical Item (L-Cat) Self-report measure of a single item comprising six descriptive categories ranging from inactive to very active Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2